Overview

Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support

Status:
Completed
Trial end date:
2019-11-21
Target enrollment:
Participant gender:
Summary
Part A:once weekly dosing for 4 weeks in patients with short bowel syndrome who require total parenteral nutrition; patients will complete period 1 and after a 6-10 week wash-out, they will enter period 2 (active treatment and placebo); Part B: treatment period 3, is an open label extension to part A and starts after a washout of 6-10 weeks after the last dose in treatment period 2. patients are dosed once weekly for 4 weeks.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
GLyPharma Therapeutic
GlyPharma Therapeutics
Collaborator:
VectivBio AG
Treatments:
Glucagon
Glucagon-Like Peptide 1